|1.||Fleck, Penny R: 5 articles (05/2015 - 12/2008)|
|2.||Fleck, Penny: 5 articles (12/2014 - 03/2008)|
|3.||Wilson, Craig: 4 articles (05/2015 - 10/2011)|
|4.||Wilson, C: 4 articles (12/2014 - 02/2009)|
|5.||Karim, Aziz: 4 articles (11/2009 - 03/2008)|
|6.||Mekki, Qais: 4 articles (11/2009 - 12/2008)|
|7.||Kaku, K: 3 articles (12/2015 - 11/2011)|
|8.||Bakris, George L: 3 articles (05/2015 - 10/2011)|
|9.||White, William B: 3 articles (05/2015 - 10/2011)|
|10.||Cannon, Christopher P: 3 articles (05/2015 - 10/2011)|
01/01/2015 - "(3) glycemic efficacy of alogliptin appears to be determined by the balance of its capacity in modulating insulin resistance and beta-cell function."
01/01/2014 - "No significant differences were seen in insulin secretory ability of homeostasis model assessment (HOMA) (HOMA-β) and insulin resistance index of HOMA (HOMA-R) before and after alogliptin treatment. "
01/01/2010 - "An alogliptin-pioglitazone combination is advantageous because it addresses both insulin resistance and islet dysfunction in T2DM. "
01/14/2009 - "These results indicate that combination treatment with alogliptin and pioglitazone improved glycemic control, lipid profiles and increased pancreatic insulin content in ob/ob mice by preventing incretin inactivation and improving insulin resistance. "
11/01/2013 - "Alogliptin treatment improved the AGE-RAGE axis and reduced albuminuria in Japanese type 2 diabetes patients."
01/01/2014 - "DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy."
11/01/2013 - "Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes."
11/01/2013 - "To examine the effects of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the advanced glycation end product (AGE)-receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes patients. "
|3.||Type 2 Diabetes Mellitus (MODY)
11/01/2013 - "To review the pharmacology, pharmacokinetics, safety, and efficacy of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor in the management of type 2 diabetes mellitus (T2DM). "
02/01/2015 - "The purpose of this review is to highlight the clinical studies that led to Food and Drug Administration approval of alogliptin and to provide insight into the place in therapy for the management of type 2 diabetes mellitus. "
11/01/2013 - "[The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China]."
10/01/2012 - "In a randomized, double-blind trial, 288 patients with type 2 diabetes mellitus T2DM received either 12.5 or 25 mg alogliptin once daily + metformin or placebo + metformin for 12 weeks. "
09/01/2011 - "Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study."
05/23/2015 - "Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial."
05/23/2015 - "Alogliptin had no effect on composite events of cardiovascular death and hospital admission for heart failure in the post hoc analysis (HR 1·00, 95% CI 0·82-1·21) and results did not differ by baseline BNP concentration. "
05/23/2015 - "Hospital admission for heart failure was the first event in 85 (3·1%) patients taking alogliptin compared with 79 (2·9%) taking placebo (HR 1·07, 95% CI 0·79-1·46). "
05/01/2014 - "The effect of alogliptin on hospitalisations for heart failure has not been reported. "
06/01/2015 - "We investigated the effects of a DPP-4 inhibitor, alogliptin, on atrial fibrillation (AF) in a rabbit model of heart failure caused by ventricular tachypacing (VTP). "
11/01/2010 - "Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus."
05/01/2014 - "The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus - Thrombolysis in Myocardial Infarction 53 trial and Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care were both multicentre, randomised, double-blind, placebo-controlled, Phase IV clinical trials. "
07/01/2014 - "Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)]."
07/08/2013 - "Efficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring."
10/01/2015 - "According to the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53) and EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE) trials, DPP4 inhibitors, including saxagliptin and alogliptin, did not appear to increase the risk of CV events in patients with type 2 diabetes and established CVD or high risk factors. "
|8.||Type 1 Angiotensin Receptor
|9.||advanced glycosylation end-product receptor
|1.||Cardiac Resynchronization Therapy
|3.||Renal Dialysis (Hemodialysis)
|4.||Exercise Therapy (Therapy, Exercise)
|5.||Drug Therapy (Chemotherapy)